Loading stock data…
PRAX
$324.20+5.37 (+1.68%)
Market ClosedLast close May 1
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Praxis Precision Medicines, Inc. in the Healthcare sector is trading at $324.20. The stock is currently near its 52-week high of $356.00, remaining 60.0% above its 200-day moving average. Technical signals show neutral RSI of 53 and bearish MACD signal, explaining why PRAX maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 53) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$324.20
Potential Upside
5%
Whystock Fair Value$340.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Mean target$634.65+95.8%
Range$130.00 – $1245
Fundamentals
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-28.58%
Volume
Today's trading volume
323,637
Recent News
Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 10 best biotech stocks with highest upside potential. As of the close of play on April 24, the broader consensus sentiments towards Praxis Precision Medicines Inc. (NASDAQ:PRAX) remained strongly bullish. The stock received coverage from 16 analysts, 14 of whom assigned Buy ratings and 1 gave […]
Praxis Precision Medicines Inc. (PRAX): Rare Triple-Catalyst Setup in Neurology
We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Praxis Precision Medicines, Inc. (NASDAQ:PRAX) ranks 1st on this list. Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is still pre-revenue but Wall Street is piling into the stock because of a rare triple-catalyst setup in neurology. There are two major regulatory decisions […]
Praxis Precision Medicines (PRAX): One of the Best Upside Stocks
Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 9 Best Upside Stocks to Buy According to Analysts. Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best upside stocks to buy according to analysts. On April 14, Praxis Precision Medicines announced that the US FDA accepted its NDA for ulixacaltamide HCl. This treatment is […]
FDA Moves Ulixacaltamide Forward As Praxis Valuation Gap Draws Focus
The U.S. FDA has accepted Praxis Precision Medicines' New Drug Application for ulixacaltamide to treat essential tremor. The agency has also granted ulixacaltamide Breakthrough Therapy Designation. The NDA is supported by late stage clinical trial data in patients with essential tremor. Praxis Precision Medicines, listed as NasdaqGS:PRAX, focuses on treatments for central nervous system disorders, including movement disorders such as essential tremor. This latest FDA step places...
Why Praxis, A Top 1% Biotech, Just Surged Into A Bullish Breakout
Praxis, a top biotech stock, surged Tuesday after the FDA assigned a potential approval date for its essential tremor treatment.